https://pubmed.ncbi.nlm.nih.gov/38112806

This phase I clinical trial suggests that allogeneic Wharton’s jelly-derived mesenchymal stem cell (WJ-MSC) transplantation in patients with type 2 diabetes and critical limb ischemia (CLI) is safe and potentially effective in improving pain, mobility, and avoiding amputation.